15 reports

  • Pipeline analysis

Sotagliflozin is a small molecule and exhibits its mechanism by inhibiting SGLT-##, which helps absorb glucose and galactose in the gastrointestinal (GI) tract, and SGLT-##, which helps in glucose reabsorption by the kidney.

  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

NIHS' research categories comprise brain health, molecular nutrition, system science, cell biology, mitochondrial function, omics, informatics, cognitive health and ageing, metabolic health, and gastrointestinal health.

  • Therapy
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • ViaCyte, Inc.
  • Dec 05, 2016: Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration...

Most carcinoid tumors are found in the gastrointestinal tract.

  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes
  • United States
  • Lexicon Pharmaceuticals, Inc.
  • TYPE 1 DIABETES (JUVENILE DIABETES) - PIPELINE BY REGIMMUNE CORPORATION, H2 2016
  • TYPE 1 DIABETES (JUVENILE DIABETES) - DORMANT PROJECTS (CONTD..10), H2 2016

It discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Biotechnology
  • Type 1 Diabetes
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • PIPELINE BY GLAXOSMITHKLINE PLC, H1 2016

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Diabetes
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • Xencor, Inc.

" Until recently it has been generally accepted that despite the convenience and appeal of oral therapies, immunotherapies could not be administered orally because they would be degraded and inactivated by the harsh conditions in the gastrointestinal tract, " commented Gabriele Cerr

  • Therapy
  • Type 1 Diabetes
  • United States
  • World
  • Product Initiative

The researchers found that IDegLira was also associated with decreased systolic blood pressure but more " non-serious" gastrointestinal side effects - mainly nausea.

  • Drug Discovery And Development
  • Insulin
  • Type 1 Diabetes
  • World
  • Product Initiative
  • MELIOR DISCOVERY INC
  • SYNTHETIC PEPTIDE TO AGONIZE NK1 FOR TYPE 1 DIABETES - DRUG PROFILE

Its pipeline candidates are used to treat the Gastrointestinal/ CRC and orphan diseases.

  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative
  • REDHILL BIOPHARMA LTD.
  • TYPE 1 DIABETES (JUVENILE DIABETES) - DORMANT PROJECTS (CONTD..12), H2 2016

Its pipeline candidates are used to treat the Gastrointestinal/ CRC and orphan diseases.

  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative
  • Latest Clinical Trials News on Type 1 Diabetes (Juvenile Diabetes)

AS AN ORAL AGENT, LX## IS DESIGNED TO DELAY THE ABSORPTION OF GLUCOSE IN THE GASTROINTESTINAL TRACT AND ENHANCE GLUCOSE EXCRETION IN THE KIDNEY, ALLOWING GLUCOSE CONTROL TO IMPROVE AND INSULIN DOSES TO BE REDUCED.

  • Drug Discovery And Development
  • Type 1 Diabetes
  • United States
  • World
  • Novo Nordisk Group